Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H15F3N4O3.ClH |
| Molecular Weight | 440.804 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.NC1CCN(C1)C2=NC3=C(C=C2F)C(=O)C(=CN3C4=CC=C(F)C=C4F)C(O)=O
InChI
InChIKey=CIHZSSCESOLBRQ-UHFFFAOYSA-N
InChI=1S/C19H15F3N4O3.ClH/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C19H15F3N4O3 |
| Molecular Weight | 404.3426 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: description was created based on several sources, including:
http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf
Curator's Comment: description was created based on several sources, including:
http://medical.taishotoyama.co.jp/data/if/pdf/ozx.pdf
Tosufloxacin is a fluoroquinolone antibacterial agent. Tosufloxacin is an inhibitor of bacterial DNA gyrase and topoisomerase IV. Tosufloxacin is indicated for the treatment of various infections such as skin, respiratory, urinary, gynecologic, ophthalmologic, otolaryngologic, dental infections. Fluoroquinolones including tosufloxacin have a potential risk of inducing cartilage and joint toxicity in children. It is also associated with severe thrombocytopenia and nephritis, and hepatotoxicity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2311224 |
|||
Target ID: CHEMBL2363076 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1990 |
|||
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1990 |
|||
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1991 |
|||
| Curative | Ozex Approved UseIt is usually used to treat various infections such as skin/respiratory/urinary/gynecologic/ophthalmologic/otolaryngologic/dental infections. Launch Date1990 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990. | 1993 Apr |
|
| In-vitro activity of quinolones and macrolides against mycobacteria. | 1994 Sep |
|
| Trovafloxacin is active against Toxoplasma gondii. | 1996 Aug |
|
| Therapeutic effect of the quinolone prodrug prulifloxacin against experimental urinary tract infections in mice. | 1996 Dec |
|
| N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies. | 1996 Nov |
|
| Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. | 1996 Oct |
|
| [In vitro anti-MAC activities of new quinolones in focus (2)]. | 1996 Sep |
|
| Dual inhibitory activity of sitafloxacin (DU-6859a) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae. | 1999 Oct |
|
| In vitro method for prediction of the phototoxic potentials of fluoroquinolones. | 2001 Dec |
|
| [An adult case of systemic cat-scratch disease with hepatosplenic involvement]. | 2001 Jun |
|
| A comparative study of the fluoroquinolone antibacterial agents on the action potential duration in guinea pig ventricular myocardia. | 2001 Nov |
|
| In-vitro activity of moxifloxacin and other fluoroquinolones against Chlamydia species. | 2002 Mar |
|
| Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin. | 2002 Mar |
|
| [The history of the development and changes of quinolone antibacterial agents]. | 2003 |
|
| [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. | 2003 Feb |
|
| [Salmonella infections]. | 2003 Feb |
|
| Terbium sensitized determination of tosufloxacin using electrochemiluminescence method. | 2005 Apr |
|
| In vitro activity of pazufloxacin, tosufloxacin and other quinolones against Legionella species. | 2005 Dec |
|
| [Clinical study of male urethritis in Oogaki Municipal Hospital]. | 2005 Jan |
|
| Prevalence of Ile-460-Val/ParE substitution in clinical Streptococcus pneumoniae isolates that were less susceptible to fluoroquinolones. | 2005 Jul |
|
| Antimicrobial activities of tosufloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella branhamella catarrhalis isolated from otolaryngological infectious diseases. | 2005 Oct |
|
| Pharmacodynamic evaluation of tosufloxacin against Streptococcus pneumoniae in an in vitro model simulating serum concentration. | 2006 Feb |
|
| In vitro activity of sitafloxacin compared with several fluoroquinolones against Streptococcus anginosus and Streptococcus constellatus. | 2006 Feb |
|
| [Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibiotics in Gifu prefecture (2004)]. | 2006 Jun |
|
| Antibacterial activity of tosufloxacin against major organisms detected from patients with respiratory or otorhinological infections: comparison with the results obtained from organisms isolated about 10 years ago. | 2006 Jun |
|
| Multidrug-resistant typhoid fever outbreak in travelers returning from Bangladesh. | 2007 Dec |
|
| [A case of acute bronchitis caused by Neisseria meningitidis associated with HIV infection]. | 2007 Nov |
|
| Mutations in the quinolone resistance determining region in Staphylococcus epidermidis recovered from conjunctiva and their association with susceptibility to various fluoroquinolones. | 2008 Jun |
|
| Quantitative comparison of the convulsive activity of combinations of twelve fluoroquinolones with five nonsteroidal antiinflammatory agents. | 2009 |
|
| Fluoroquinolones reduce carrageenan-induced edema in rats and the involvement of the glucocorticoid receptor system. | 2009 Apr |
|
| Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. | 2009 Feb |
|
| Corneal deposits after topical tosufloxacin in a patient with poor tear secretion. | 2009 Jan |
|
| [Antibacterial activity of quinolones against various clinically isolated strains and evaluation of efficacy based on the pharmacokinetics/pharmacodynamics theory]. | 2009 Jun |
|
| [Efficacy of tosufloxacin in genital chlamydial infections]. | 2009 Oct |
|
| [Intractable pediatric infectious disease: examining the ability of a new drug, tosufloxacin tosilate hydrate for pediatric]. | 2010 Dec |
|
| Risk factors for acute prostatitis after transrectal biopsy of the prostate. | 2010 Jun |
Patents
Sample Use Guides
In general, for adults, take 2 to 3 tablets (300 to 450 mg of the active ingredient) a day, in 2 to 3 divided doses. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Osteomyelitis, arthritis: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 3 times a day. The dosage may be adjusted according to disease, symptoms, etc. of the patient. If symptoms are severe or the effect is insufficient, take 4 tablets (600 mg) a day.
Typhoid/paratyphoid fever: In general, for adults, take 1 tablet (150 mg of the active ingredient) at a time, 4 times a day for 14 days.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:23:54 GMT 2023
by
admin
on
Sat Dec 16 09:23:54 GMT 2023
|
| Record UNII |
M1FK9581QZ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID60908770
Created by
admin on Sat Dec 16 09:23:54 GMT 2023 , Edited by admin on Sat Dec 16 09:23:54 GMT 2023
|
PRIMARY | |||
|
100490-92-4
Created by
admin on Sat Dec 16 09:23:54 GMT 2023 , Edited by admin on Sat Dec 16 09:23:54 GMT 2023
|
NON-SPECIFIC STOICHIOMETRY | |||
|
M1FK9581QZ
Created by
admin on Sat Dec 16 09:23:54 GMT 2023 , Edited by admin on Sat Dec 16 09:23:54 GMT 2023
|
PRIMARY | |||
|
100000176623
Created by
admin on Sat Dec 16 09:23:54 GMT 2023 , Edited by admin on Sat Dec 16 09:23:54 GMT 2023
|
PRIMARY | |||
|
m10984
Created by
admin on Sat Dec 16 09:23:54 GMT 2023 , Edited by admin on Sat Dec 16 09:23:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
10433396
Created by
admin on Sat Dec 16 09:23:54 GMT 2023 , Edited by admin on Sat Dec 16 09:23:54 GMT 2023
|
PRIMARY | |||
|
104051-69-6
Created by
admin on Sat Dec 16 09:23:54 GMT 2023 , Edited by admin on Sat Dec 16 09:23:54 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
